{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:38:44Z","timestamp":1793831924300,"version":"4.6.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"47","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term effects of mavacamten.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants from EXPLORER-HCM (NCT03470545) could enrol in MAVA-LTE upon study completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At the latest data cut-off, 211 (91.3%) of the 231 patients originally enrolled in MAVA-LTE still received mavacamten. Median (range) time on study was 166.1 (6.0\u2013228.1) weeks; 185 (80.1%) and 99 (42.9%) patients had completed the Week 156 and 180 visits, respectively. Sustained reductions from baseline to Week 180 occurred in left ventricular outflow tract gradients [mean (standard deviation): resting, \u221240.3 (32.7) mmHg; Valsalva, \u221255.3 (33.7) mmHg], N-terminal pro B-type natriuretic peptide [median (interquartile range): \u2212562 (\u22121162.5, \u2212209) ng\/L], and EQ-5D-5L score [mean (standard deviation): 0.09 (0.17)]. Mean left ventricular ejection fraction (LVEF) decreased from 73.9% (baseline) to 66.6% (Week 24) and 63.9% (Week 180). At Week 180, 74 (77.9%) of the 95 patients improved by at least one New York Heart Association class from baseline. Over 739 patient-years exposure, 20 patients (8.7%; exposure-adjusted incidence: 2.77\/100 patient-years) experienced 22 transient reductions in LVEF to &amp;lt;50% resulting in temporary treatment interruption (all recovered LVEF of \u226550%). Five (2.2%) patients died (all considered unrelated to mavacamten).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long-term mavacamten treatment resulted in sustained improvements in cardiac function and symptoms in patients with obstructive HCM, with no new safety concerns identified. Transient, reversible reductions in LVEF were observed in a small proportion of patients during long-term follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae579","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T01:20:15Z","timestamp":1724289615000},"page":"5071-5083","source":"Crossref","is-referenced-by-count":114,"title":["Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV , Manuel de Falla 2, 28222, Madrid ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]},{"name":"Universidad Francisco de Vitoria (UFV) , Pozuelo de Alarcon ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3318-3643","authenticated-orcid":false,"given":"Artur","family":"Or\u0119ziak","sequence":"additional","affiliation":[{"name":"Department of Arrhythmia, National Institute of Cardiology , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-3487","authenticated-orcid":false,"given":"Roberto","family":"Barriales-Villa","sequence":"additional","affiliation":[{"name":"Inherited Cardiovascular Diseases Unit, Complexo Hospitalario Universitario A Coru\u00f1a, INIBIC, CIBERCV (ISCIII) , A Coru\u00f1a ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P","family":"Abraham","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-8495","authenticated-orcid":false,"given":"Anjali T","family":"Owens","sequence":"additional","affiliation":[{"name":"Center for Inherited Cardiac Disease, Division of Cardiovascular Medicine, University of Pennsylvania, Perelman School of Medicine , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1144-4603","authenticated-orcid":false,"given":"Morten K","family":"Jensen","sequence":"additional","affiliation":[{"name":"School of Medicine, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3681-5207","authenticated-orcid":false,"given":"Wojciech","family":"Wojakowski","sequence":"additional","affiliation":[{"name":"Chief Division of Cardiology and Structural Heart Diseases, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6158-5087","authenticated-orcid":false,"given":"Tim","family":"Seidler","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pulmonology, University of G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]},{"name":"Cardiology, Kerckhoff Clinic , Bad Nauheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4685-6077","authenticated-orcid":false,"given":"Albert","family":"Hagege","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal K","family":"Lakdawala","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8729-0933","authenticated-orcid":false,"given":"Andrew","family":"Wang","sequence":"additional","affiliation":[{"name":"Cardiology, Duke University Hospital , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-3022","authenticated-orcid":false,"given":"Matthew T","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Stanford University School of Medicine , Stanford, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4039-8490","authenticated-orcid":false,"given":"Lubna","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Balaratnam","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Shah","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawna","family":"Fox","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8157-8899","authenticated-orcid":false,"given":"Sheila M","family":"Hegde","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-9266","authenticated-orcid":false,"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Meyer Children\u2019s Hospital, IRCCS , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,1]]},"reference":[{"key":"2024121523540416500_ehae579-B1","doi-asserted-by":"publisher","first-page":"e24634","DOI":"10.7554\/eLife.24634","article-title":"Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes","volume":"6","author":"Alamo","year":"2017","journal-title":"eLife"},{"key":"2024121523540416500_ehae579-B2","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2024121523540416500_ehae579-B3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.hfc.2017.12.004","article-title":"Genetic pathogenesis of hypertrophic and dilated cardiomyopathy","volume":"14","author":"Garfinkel","year":"2018","journal-title":"Heart Fail Clin"},{"key":"2024121523540416500_ehae579-B4","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2024121523540416500_ehae579-B5","doi-asserted-by":"publisher","first-page":"ehac544.1747","DOI":"10.1093\/eurheartj\/ehac544.1747","article-title":"Population estimates of obstructive and non-obstructive hypertrophic cardiomyopathy in the UK and Germany","volume":"43","author":"Schultze","year":"2022","journal-title":"Eur Heart J"},{"key":"2024121523540416500_ehae579-B6","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"2024121523540416500_ehae579-B7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"2024121523540416500_ehae579-B8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s41687-020-00269-8","article-title":"Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life","volume":"4","author":"Zaiser","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2024121523540416500_ehae579-B9","author":"CAMZYOS (mavacamten)"},{"key":"2024121523540416500_ehae579-B10","author":"CAMZYOS (mavacamten)"},{"key":"2024121523540416500_ehae579-B11","author":"CAMZYOS (mavacamten)"},{"key":"2024121523540416500_ehae579-B12","author":"CAMZYOS (mavacamteno)"},{"key":"2024121523540416500_ehae579-B13","author":"CAMZYOS (mavacamtenum)"},{"key":"2024121523540416500_ehae579-B14","author":"CAMZYOS (mavacamten)"},{"key":"2024121523540416500_ehae579-B15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2024121523540416500_ehae579-B16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2024121523540416500_ehae579-B17","doi-asserted-by":"publisher","first-page":"e006853","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2024121523540416500_ehae579-B18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s41669-022-00335-5","article-title":"Development of the hypertrophic cardiomyopathy symptom questionnaire (HCMSQ): a new patient-reported outcome (PRO) instrument","volume":"6","author":"Reaney","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"2024121523540416500_ehae579-B19","doi-asserted-by":"publisher","first-page":"e001002","DOI":"10.1161\/JAHA.114.001002","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population","volume":"3","author":"Siontis","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2024121523540416500_ehae579-B20","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2024121523540416500_ehae579-B21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/ejhf.2861","article-title":"Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation","volume":"25","author":"Filippatos","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2024121523540416500_ehae579-B22","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024121523540416500_ehae579-B23","doi-asserted-by":"publisher","first-page":"e009427","DOI":"10.1161\/CIRCHEARTFAILURE.121.009427","article-title":"Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort","volume":"15","author":"Welsh","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2024121523540416500_ehae579-B24","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehae579\/58905992\/ehae579.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/47\/5071\/61151919\/ehae579.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/47\/5071\/61151919\/ehae579.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T18:54:20Z","timestamp":1734288860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/47\/5071\/7739956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":24,"journal-issue":{"issue":"47","published-online":{"date-parts":[[2024,9,1]]},"published-print":{"date-parts":[[2024,12,16]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae579","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,14]]},"published":{"date-parts":[[2024,9,1]]}}}